Guardant Health Expands Guardant Reveal Blood Test To Monitor Late-Stage Cancer Therapy Response

Author: Benzinga Newsdesk | November 10, 2025 08:13am

• New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity
• Reveal is clinically validated in confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient's blood to predict outcomes sooner than imaging without the need for a tissue sample.

Building on Reveal's proven performance in minimal residual disease (MRD) detection, the expanded offering leverages Guardant's proprietary epigenomic technology powered by the Guardant Infinity Smart Platform to predict therapy response across all therapy classes, including immunotherapy and chemotherapy, which most patients with advanced-stage cancer receive at some point during their treatment. Guardant Reveal therapy response monitoring can be initiated at any time during a patient's treatment journey, offering clinicians flexibility and actionable insights in just seven days.

Posted In: GH